Teva : An attractive value proposal amid the current market sell-off
We have had a 'Reduce' stance on most bonds so far (apart from 'Neutral' on the € 1bn issue due in July) and we stayed away from the € 2.1bn issue in November as signs of turnaround remained tepid and, above all, exposure to opioid litigation was almost impossible to quantify. - We are now adopting a more positive view as underlying markets are improving, notably the key US market where price pressure is abating. Meanwhile, most overseas markets, led by Europe, are robust. In addit...Teva Pharmaceutical Industries is engaged in the development, manufacturing, marketing and distribution of generic, specialty, and other pharmaceutical products. The Generic Medicines segment offers a range of basic chemical entities, as well as specialized product families such as sterile products, hormones, narcotics, high-potency drugs and cytotoxic substances, in both parenteral and solid dosage forms. Co.'s specialty medicines business is focused on delivering innovative solutions to patients and providers via medicines, devices and services, includes Co.'s core therapeutic areas of the central nervous system and respiratory medicines.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.